Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1417 - Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety

    Primary Author / Presenter(s)

  • KZ

    Ken Zou, BA

    Medical Student
    UT Southwestern Medical Center
    Dallas, Texas, United States

    • Co-Author(s)

  • RM

    Rudy Mrad, MD

    UT Southwestern Medical Center
    Dallas, Texas, United States

  • HW

    Heather R. Wolfe, MD

    UT Southwestern Medical Center
    Dallas, Texas, United States

  • FA

    Farrukh T. Awan, MD

    Associate Professor and Director of Lymphoid Malignancies Program at UTSW
    The University of Texas Southwestern
    Dallas, Texas, United States